CLL
From the Journals
Frontline ibrutinib saves money over chemoimmunotherapy
An analysis of claims data for more than 1,000 patients with chronic lymphocytic leukemia shows that ibrutinib monotherapy is a less expensive...
From the Journals
Gene signature may help guide initial CLL treatment choice
A 17-gene expression signature may help predict which patients with IGHV-unmutated disease will benefit from frontline FCR chemoimmunotherapy or...
Conference Coverage
Consider renal function in TLS risk assessment of venetoclax-treated CLL
EDINBURGH – Impaired renal function may indicate excess risk of tumor lysis syndrome (TLS) in venetoclax-treated...
Conference Coverage
PJP prophylaxis may be unnecessary for CLL patients on BTK inhibitors
EDINBURGH – The findings show an overall low pneumocystis jiroveci pneumonia prevalence in patients not receiving prophylaxis.
Conference Coverage
Targeted agents vs. chemoimmunotherapy as first-line treatment of CLL
SAN FRANCISCO – Experts debate the role of chemoimmunotherapy as first-line treatment of chronic lymphocytic leukemia.
Conference Coverage
German CLLM1 study: 4-year data raise concerns about lenalidomide maintenance
EDINBURGH – Four-year data from the CLLM1 study of lenalidomide maintenance after chemoimmunotherapy for CLL showed improved PFS and EFS versus...
Conference Coverage
ICLL-07 trial: MRD-driven strategy yields prolonged survival
EDINBURGH - In the phase 2 ICLL-07 trial, induction with obinutuzumab and ibrutinib followed by an MRD-driven treatment strategy for CLL yielded a...
Conference Coverage
GALACTIC CLL trial: Obinutuzumab consolidation helps eradicate MRD
EDINBURGH – Obinutuzumab consolidation after chemoimmunotherapy for B-CLL was highly effective for eradicating MRD within 6 months post...
From the Journals
CK doesn’t seem to affect OS in CLL patients taking idelalisib
Data from two clinical trials of idelalisib showed no significant difference in overall survival between patients with and without complex...
News
Calquence earns breakthrough designation for CLL monotherapy
The Bruton tyrosine kinase inhibitor is already approved for the treatment of adults with mantle cell lymphoma who have received at least one...
From the Journals
Zanubrutinib may be poised to challenge ibrutinib for CLL
The phase 1 study had a 96% overall response rate and there were no dose-limiting toxicities.